Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Carney
Dennis A
DA
Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia. dennis.carney@petermac.org
Seymour
John F
JF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D018570:Risk Assessment; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D014740:Vidarabine; C024352:fludarabine